

In one aspect, the present disclosure is directed to use of a compound of structural formula:



or a pharmaceutically acceptable salt thereof,


in the manufacture of a medicament for the inhibition of HIV reverse transcriptase, the treatment of HIV infection, the treatment of AIDS or ARC, the delay in the onset of AIDS or ARC, or the prophylaxis of HIV infection, AIDS or ARC in a subject, wherein the compound or a pharmaceutically acceptable salt thereof is to be administered at a dosing regimen which is once-weekly, once bi-weekly, twice-monthly or once-monthly and wherein the subject is human.

In another aspect, the present disclosure is directed to use of a compound of structural formula:



or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prophylaxis of HIV infection in a subject not infected with HIV, wherein the subject is human.

In another aspect, the present disclosure is directed to use of a compound of structural formula:




or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the inhibition of HIV reverse transcriptase, the treatment of HIV infection, the treatment of AIDS or ARC, the delay in the onset of AIDS or ARC, or the prophylaxis of HIV infection, AIDS or ARC in a subject, wherein the compound or a pharmaceutically

acceptable salt thereof is to be administered parenterally at a dosing regimen which is once-weekly, once bi-weekly, twice-monthly, once-monthly, once-quarterly, twice-yearly, once-yearly, once every 18 months or bi-annually.

The present disclosure also encompasses treatment of a subject infected with HIV by parenteral administration of EFdA or ECdA, or a pharmaceutically acceptable salt or co-

WHAT IS CLAIMED IS:

1. Use of a compound of structural formula:



or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the inhibition of HIV reverse transcriptase, the treatment of HIV infection, the treatment of AIDS or ARC, the delay in the onset of AIDS or ARC, or the prophylaxis of HIV infection, AIDS or ARC in a subject, wherein the compound or a pharmaceutically acceptable salt thereof is to be administered at a dosing regimen which is once-weekly, once bi-weekly, twice-monthly or once-monthly and wherein the subject is human.

2. The use according to claim 1 for the inhibition of HIV reverse transcriptase, the treatment of HIV infection, the treatment of AIDS or ARC, or delay in the onset of AIDS or ARC, wherein the compound or a pharmaceutically acceptable salt thereof is to be administered orally.

3. The or use according to claim 2 wherein the dosing regimen is once-weekly.

4. The use according to claim 3 wherein the dosage amount is from 1 mg to 50 mg at each administration.

5. The use according to claim 3 wherein the dosage amount is from 1 mg to 20 mg at each administration.

6. The use according to claim 3 wherein the dosage amount is 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg or 10 mg at each administration.

7. The use according to claim 1 wherein the dosing regimen is once bi-weekly or twice monthly.

8. The use according to claim 7 wherein the dosage amount is from 2 mg to 100 mg at each administration.

9. The use according to claim 7 wherein the dosage amount is from 2 mg to 40 mg at each administration.

10. The use according to claim 7 wherein the dosage amount is 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg or 20 mg at each administration.


11. The use according to claim 1 wherein the dosing regimen is once-monthly.

12. The use according to claim 11 wherein the dosage amount is from 4 mg to 200 mg at each administration.

13. The use according to claim 11 wherein the dosage amount is from 4 mg to 80 mg at each administration.

14. The use according to claim 11 wherein the dosage amount is 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg or 20 mg; 21mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg or 30 mg, 31mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg or 40 mg at each administration.

15. Use of a compound of structural formula:



or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prophylaxis of HIV infection in a subjected not infected with HIV, wherein the subject is a human.

16. The use according to claim 1 for the prophylaxis of HIV infection, or the use according to claim 15, wherein the compound or a pharmaceutically acceptable salt thereof is to be administered orally.

17. The use according to claim 16 wherein the dosing regimen is once-weekly.

18. The use according to claim 17 wherein the dosage amount is from 1 mg to 20 mg at each administration.

19. The use according to claim 17 wherein the dosage amount is 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg or 10 mg at each administration.

20. The use according to claim 16 wherein the dosing regimen is once bi-weekly, or twice-monthly.

21. The use according to claim 20 wherein the dosage amount is from 2 mg to 100 mg at each administration.

22. The use according to claim 20 wherein the dosage amount is from 2 mg to 40 mg at each administration.

23. The use according to claim 20 wherein the dosage amount is 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg or 20 mg at each administration.


24. The use according to claim 16 wherein the dosing regimen is once-monthly.

25. The use according to claim 24 wherein the dosage amount is from 4 mg to 200 mg at each administration.

26. The use according to claim 24 wherein the dosage amount is from 4 mg to 80 mg at each administration.

27. The use according to claim 24 wherein the dosage amount is 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg or 20 mg; 21mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg or 30 mg, 31mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg or 40 mg at each administration.

28 Use of a compound of structural formula:



or a pharmaceutically acceptable salt thereof,


in the manufacture of a medicament for the inhibition of HIV reverse transcriptase, the treatment of HIV infection, the treatment of AIDS or ARC, the delay in the onset of AIDS or ARC, or the prophylaxis of HIV infection, AIDS or ARC in a subject, wherein the compound or a pharmaceutically acceptable salt thereof is to be administered parenterally at a dosing regimen which is once-weekly, once bi-weekly, twice-monthly, once-monthly, once-quarterly, twice-yearly, once-yearly, once every 18 months or bi-annually.

29. The use according to claim 28 wherein the subject is human.

30. The use according to claim 29 wherein the compound or a pharmaceutically acceptable salt thereof is to be administered by infusion once-weekly, once bi-weekly, twice-monthly, once-monthly, once-quarterly, twice-yearly or once-yearly.

31. The use according to claim 29 wherein the compound or a pharmaceutically acceptable salt thereof is to be administered by an implantable drug delivery composition and the dosing regimen is once-monthly, once-quarterly, twice-yearly, once-yearly, once every 18 months or bi-annually.

32. The use according to any one of claims 1 to 31 wherein the compound is



.

33. The use according to any one of claims 1 to 32 wherein the HIV is HIV-1.